Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) on January 28, 2026. The report details significant changes to the Company's Board of Directors, including the retirement of a long-serving director, the appointment of a new director, and amendments to the director compensation plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Retirement of Director: Dr. Jay Birnbaum retired from the Board effective January 28, 2026, after serving since April 2007.
- Appointment of Director: Ms. Vanessa Jacoby was appointed as a new independent director effective January 28, 2026, replacing Dr. Birnbaum. She was also appointed Chairperson of the Audit Committee and a member of the Compensation Committee.
- Compensation Plan Amendment: The Board adopted a revised Non-Employee Director Compensation Program to allow discretion in the number of options granted and the form of initial equity grants.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance or operational outlook. Management expressed gratitude for Dr. Birnbaum's service and highlighted Ms. Jacoby's extensive experience in biotechnology finance, including roles as CFO at Shoreline Biosciences and Chief Business and Financial Officer at Quanta Therapeutics, Inc.
Compensation Details
- Dr. Jay Birnbaum (Consulting): Will receive 5,000 Restricted Stock Units (RSUs) per quarter for a one-year term. These RSUs vest on the second business day after the filing of the 10-K for the year ended March 31, 2027, or upon a change of control.
- Ms. Vanessa Jacoby (Director):
- Annual retainer: $32,500.
- Audit Committee Chair fee: $10,000 annually.
- Compensation Committee member fee: $7,500 annually.
- Initial Equity Grant: Options to purchase 10,000 shares, vesting in three equal installments over three years.
Investor Verification Checklist
- Verify the full text of the Consulting Agreement with Dr. Birnbaum (Exhibit 10.1) for specific terms regarding the RSUs and vesting conditions.
- Review the revised Non-Employee Director Compensation Program (Exhibit 10.2) to understand the new discretion granted to the Board regarding equity grants.
- Confirm Ms. Jacoby's background and potential conflicts of interest given her current role at Quanta Therapeutics, Inc.
- Monitor the upcoming 10-K filing for the year ended March 31, 2027, as it triggers the vesting of Dr. Birnbaum's RSUs.